OncoTherapy Science, Inc. (TYO:4564)
21.00
+1.00 (5.00%)
At close: Mar 6, 2026
OncoTherapy Science Revenue
OncoTherapy Science had revenue of 166.00M JPY in the quarter ending December 31, 2025, a decrease of -50.89%. This brings the company's revenue in the last twelve months to 784.00M, up 10.89% year-over-year. In the fiscal year ending March 31, 2025, OncoTherapy Science had annual revenue of 750.00M with 22.95% growth.
Revenue (ttm)
784.00M
Revenue Growth
+10.89%
P/S Ratio
10.09
Revenue / Employee
16.68M
Employees
47
Market Cap
7.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 750.00M | 140.00M | 22.95% |
| Mar 31, 2024 | 610.00M | -524.00M | -46.21% |
| Mar 31, 2023 | 1.13B | -19.00M | -1.65% |
| Mar 31, 2022 | 1.15B | 821.00M | 247.29% |
| Mar 31, 2021 | 332.00M | 16.00M | 5.06% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Linical | 9.32B |
| Soiken Holdings | 4.58B |
| CellSource | 3.71B |
| StemCell Institute | 2.78B |
| MEDINET | 998.00M |
| PRISM BioLab Co.,LTD | 684.61M |
| Chiome Bioscience | 593.29M |
| ADR120S | 40.00M |